MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejso.2026.112026

Медицинская библиотека · European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2026

Preoperative chemoimmunotherapy vs chemoradiotherapy in cT4 ESCC: a multicenter retrospective study.

Zhang Kanghua, Yuan Chang, Chen Xiaofang, Guo Chenglong, Zhao Jia, Li Zhigang, Zhang Guoqing, Li Xiangnan

Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

IMPORTANCE

Clinical T4 (cT4) esophageal squamous cell carcinoma (ESCC) remains challenging, and evidence for preoperative strategies in surgical candidates is limited.

DESIGN

Retrospective study at 3 centers in China. Patients with AJCC 8th edition clinical T4 ESCC who received preoperative chemoimmunotherapy (pre-CIT) or preoperative chemoradiotherapy (pre-CRT), underwent reassessment, and completed esophagectomy were included in the primary surgical cohort (n = 235; pre-CIT 124, pre-CRT 111). Propensity score matching was performed to reduce baseline imbalances, and additional analyses restricted to patients who achieved R0 resection were performed as supplementary analyses.

MAIN OUTCOMES: Two-year OS and DFS were higher in the pre-CIT group than in the pre-CRT group (OS, 76.4% vs 55.2%; P = 0.032; DFS, 73.6% vs 51.6%; P = 0.024). In multivariable Cox models with pre-CIT as the reference, pre-CRT was associated with worse OS (HR, 1.80; 95% CI, 1.07-3.02; P = 0.027) and DFS (HR, 2.01; 95% CI, 1.22-3.30; P = 0.006). After propensity score matching, pre-CIT remained associated with better OS and DFS than pre-CRT. Overall postoperative complications were comparable between groups (Clavien-Dindo grade ≥ I, 59.7% vs 63.1%; P = 0.595), and major complications did not differ significantly (grade ≥ IIIa, 28.2% vs 36.9%; P = 0.154). Overall recurrence rates were not significantly different (21.8% vs 27.9%; P = 0.292), but distant metastasis occurred less often with pre-CIT (11.3% vs 20.7%; P = 0.048). Consistently, 2-year locoregional recurrence-free survival did not differ (83.5% vs 91.4%; P = 0.106), whereas 2-year distant metastasis-free survival favored pre-CIT (87.2% vs 71.2%; P = 0.044). After propensity score matching, neither locoregional recurrence-free survival nor distant metastasis-free survival differed significantly between groups (P = 0.225 and P = 0.106, respectively).

CONCLUSIONS AND RELEVANCE: In this surgical cT4 ESCC cohort, pre-CIT was associated with improved OS/DFS. Prospective validation is warranted.

Для цитирования: Zhang Kanghua, Yuan Chang, Chen Xiaofang, Guo Chenglong, Zhao Jia, Li Zhigang, Zhang Guoqing, Li Xiangnan. Preoperative chemoimmunotherapy vs chemoradiotherapy in cT4 ESCC: a multicenter retrospective study.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2026. DOI: 10.1016/j.ejso.2026.112026.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.